Mammary Cell News Volume 10.50 | Dec 20 2018

TOP STORY

Regulation of Ca²⁺ Signaling for Drug-Resistant Breast Cancer Therapy with Mesoporous Silica Nanocapsules Encapsulated Doxorubicin/siRNA Cocktail

The doxorubicin/siRNA co-loaded mesoporous silica nanocapsules showed a synergistic therapeutic effect on drug-resistant breast cancer cells MCF-7/ADR, while had only an additive effect on drug-sensitive MCF-7 counterpart. [ACS Nano] Abstract

(Ranked by impact factor of the journal)

The WNT10B Network Is Associated with Survival and Metastases in Chemoresistant Triple-Negative Breast Cancer

Combinatorial therapy of a WNT inhibitor with doxorubicin synergistically activated apoptosis in vitro, re-sensitized patient-derived xenograft cells to doxorubicin, and repressed lung metastasis in vivo. [Cancer Res] Abstract

Upregulation of MLK4 Promotes Migratory and Invasive Potential of Breast Cancer Cells

Depletion of mixed-lineage kinase 4 (MLK4) in cell lines with high MLK4 expression impaired proliferation and anchorage-dependent colony formation. [Oncogene] Full Article

The Oral Selective Estrogen Receptor Degrader (SERD) AZD9496 Is Comparable to Fulvestrant in Antagonizing ER and Circumventing Endocrine Resistance

Researchers studied the pharmacology of a new oral SERD, AZD9496, in a panel of in vitro and in vivo endocrine-sensitive and -resistant breast cancer models. [Br J Cancer] Abstract

Mitochondria Targeting and Destabilizing Hyaluronic Acid Derivative-Based Nanoparticles for the Delivery of Lapatinib to Triple-Negative Breast Cancer

Along with the human epidermal growth factor receptor 2-independent anticancer activities of lapatinib (LPT) in triple-negative breast cancer (TNBC), apoptosis-inducing properties of (4-carboxybutyl)triphenyl phosphonium (TPP) and d-α-tocopherol succinate (TS) were introduced to amplify the anticancer activities of hyaluronic acid-TS-TPP/LPT nanoparticles for TNBC. [Biomacromolecules] Abstract

ATM-Mediated Phosphorylation of Cortactin Involved in Actin Polymerization Promotes Breast Cancer Cells Migration and Invasion

Enhanced oxidized ataxia-telangiectasia mutated (ATM) proteins were present not only in the advanced and invasive breast tumor tissues but also malignant hypoxic breast cancer cells, in the absence of DNA damage. [Cell Physiol Biochem] Full Article

Targeting the Lysosome by an Aminomethylated Riccardin D Triggers DNA Damage through Cathepsin B-Mediated Degradation of BRCA1

Scientists showed that riccardin D-N treatment drove cathepsin B translocation from the lysosomes to the nucleus, where it promoted DNA damage by suppression of the breast cancer 1 protein (BRCA1). [J Cell Mol Med] Full Article

A 3D Microvascular Network Model to Study the Impact of Hypoxia on the Extravasation Potential of Breast Cell Lines

Investigators used an in vitro model of microvascular networks in a microfluidic chip to measure the extravasation potential of breast cell lines subjected to different oxygen conditions. [Sci Rep] Full Article

lncRNA Profile Study Reveals the mRNAs and lncRNAs Associated with Docetaxel Resistance in Breast Cancer Cells

Researchers performed comprehensive RNA sequencing and analyses on two docetaxel-resistant breast cancer cell lines and their docetaxel-sensitive parental cell lines. [Sci Rep] Full Article

miR-100 Maintains Phenotype of Tumor-Associated Macrophages by Targeting mTOR to Promote Tumor Metastasis via Stat5a/IL-1ra Pathway in Mouse Breast Cancer

Scientists screened highly expressed miRNAs in tumor-associated macrophages (TAMs), and first identified that miR-100 represented a TAMs-high expression pattern and maintained TAMs phenotype by targeting mTOR signaling pathway. [Oncogenesis] Full Article

Adipocyte-Derived Il-6 and Leptin Promote Breast Cancer Metastasis via Upregulation of Lysyl Hydroxylase-2 Expression

Loss-of-function studies indicated that lysyl hydroxylase-2 knockdown suppressed cell migration and disrupted the formation of actin stress fibers in breast cancer cells and abrogated the migration induced by following coculture with adipocytes. [Cell Commun Signal] Full Article

Down-Regulated Long Non-Coding RNA RNAZFHX4-AS1 Suppresses Invasion and Migration of Breast Cancer Cells via FAT4-Dependent Hippo Signaling Pathway

Researchers explored the regulatory mechanism of long non-coding RNA ZFHX4-AS1 in breast cancer in relation to the Hippo signaling pathway. [Cancer Gene Ther] Abstract

Subscribe to one of our other 19 science newsletters such as Prostate Cell News & ESC & iPSC News.

Beyond 5 Years: Enduring Risk of Recurrence in Estrogen Receptor-Positive Breast Cancer

The authors briefly explore the epidemiology of late recurrence (>5 years after diagnosis) in patients with estrogen receptor-positive breast cancer. [Nat Rev Clin Oncol] Abstract

Hereditary Breast Cancer; Genetic Penetrance and Current Status with BRCA

Investigators summarize the role of hereditary genes, mainly BRCA1 and BRCA2, in breast cancer. [J Cell Physiol] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Xynomic Pharma Acquires Global Exclusive Rights to Phase II Ready mTORC1/2 Inhibitor from Boehringer Ingelheim

Xynomic Pharmaceuticals, Inc. plans to initiate two clinical trials in the next six to nine months, among which, one is a potentially pivotal Phase II trial combining BI 860585 with a standard-of-care treatment against breast cancer. [Xynomic Pharmaceuticals, Inc. (PR Newswire Association LLC)] Press Release

NeuClone Announces Its Sixth Biosimilar Candidate Perjeta^® (Pertuzumab) for Use in Combination Therapy with Herceptin^® (Trastuzumab)

NeuClone Pharmaceuticals Ltd. disclosed the sixth biosimilar being developed in its pipeline of monoclonal antibody products. The product is a biosimilar candidate of Perjeta^®, currently in preclinical development. Perjeta^® is FDA and EMA approved as a treatment for patients with HER2-positive early or metastatic breast cancer and is authorized for use only in combination with trastuzumab. [NeuClone Pharmaceuticals Ltd.] Press Release

Canadian Government Ending Networks of Centres of Excellence Program

Canada’s federal government is ending a 30-year-old research funding program, the Networks of Centres of Excellence, leaving researchers uncertain about where future funding will come from, The Globe and Mail reports. The program will be phased out over the course of the next three years, according to a spokesperson for Science Minister Kirsty Duncan. [The Scientist] Editorial

Plan S: The Ambitious Initiative to End the Reign of Paywalls

Efforts to eradicate paywalls have been gaining stream in Europe. Over the last few years, university consortia in several countries have been pushing for open-access agreements in negotiations that have occasionally led to heated stalemates. [The Scientist] Editorial

Australia Cuts Research Funding for Universities

Australian scientists have expressed disappointment over an AU$328.5 million cut to research funding that had been expected over the next four years. In a budget update, the government announced that it will freeze funding increases for the program that supports research, facilities, and training, including of PhDs, at universities. [Nature News] Editorial

NEW European CanCer Organisation (ECCO) 2019: European Cancer Summit
September 12-14, 2019
Brussels, Belgium

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Associate – Cancer (University of Miami)

Postdoctoral Position – Breast Cancer (Northwestern University)

Research Associate – Breast Single Cell Atlas (University of Cambridge)

Research Assistant – Breast Medical Oncology (MD Anderson Cancer Center)

Associate Researcher – Breast Cancer Biology (Icahn School of Medicine at Mount Sinai)

Senior Coordinator – Breast Medical Oncology (MD Anderson Cancer Center)

Research Fellow – Breast Cancer (International Iberian Nanotechnology Laboratory)

Master’s Student – Stem Cell Biology and Cancer (Helmholtz-Center München)

Associate Research Scientist/Postdoctoral Research Scientist – Molecular Genetics (Columbia University Medical Center)

Faculty Position – Cancer Cell Signaling (The University of New Mexico Comprehensive Cancer Center)

Postdoctoral Associate – Molecular and Cell Biology (Baylor College of Medicine)

Postdoctoral Position – Novel Cancer Gene and Therapy (University of Notre Dame)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.